Metzger Michael A sold $785K of SNDX
Metzger Michael A (Chief Executive Officer) sold 32,375 shares of Syndax Pharmaceuticals Inc (SNDX) at $24.24 ($0.78M total) on 2026-07-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price ($24.2402/share), and post-transaction holdings, with no other company event included.
Market read
Traders may note insider selling, but the disclosure lacks fundamental catalysts and is typically low-signal.
What to watch
Insider sales under 10b5-1 are often mechanically scheduled; without changes in buying activity or additional disclosures, signal strength is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Syndax Pharmaceuticals, filed by CEO Metzger.
Ticker impact
Syndax CEO Metzger sold 32,375 shares in an open-market transaction worth about $784,776 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-only and typically fades.
The filing is a Form 4 insider transaction with no accompanying company-specific news, guidance, or event described.
Market effects
No clear read-across to biotech sector fundamentals from a single CEO open-market sale.
None indicated.
None indicated.
Counterpoint
The sale may be pre-planned under a 10b5-1 plan and could reflect diversification or tax liquidity rather than bearish expectations.
Key entities
- issuerSyndax Pharmaceuticals Inc
Company whose CEO reported an open-market sale of shares via Form 4.
- insiderMetzger Michael A
CEO and director who executed the reported sale under a 10b5-1 plan.
